RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/27622530http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/27622530http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/27622530http://www.w3.org/2000/01/rdf-schema#comment"Emerging β-lactamase-mediated resistance is threatening the clinical utility of the single most prominent class of antibacterial agents used in medicine, the β-lactams. The diazabicyclooctane avibactam is able to inhibit a wider range of serine β-lactamases than has been previously observed with β-lactamase inhibitors such as the widely prescribed clavulanic acid. However, despite its broad-spectrum activity, variable levels of inhibition have been observed for molecular class D β-lactamases. In order to better understand the molecular basis and spectrum of inhibition by avibactam, we provide structural and mechanistic analysis of the compound in complex with important class A and D serine β-lactamases. Herein, we reveal the 1.7- and 2.0-Å-resolution crystal structures of avibactam covalently bound to class D β-lactamases OXA-10 and OXA-48. Furthermore, a kinetic analysis of key active-site mutants for class A β-lactamase CTX-M-15 allows us to propose a validated mechanism for avibactam-mediated β-lactamase inhibition including a unique role for S130, which acts as a general base. This study provides molecular insights that will aid in the design and development of avibactam-based chemotherapeutic agents effective against emerging drug-resistant microorganisms."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.org/dc/terms/identifier"doi:10.1021/acsinfecdis.5b00007"xsd:string
http://purl.uniprot.org/citations/27622530http://purl.org/dc/terms/identifier"doi:10.1021/acsinfecdis.5b00007"xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"Wright G.D."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"Wright G.D."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"Strynadka N.C."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"Strynadka N.C."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"King D.T."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"King D.T."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"King A.M."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"King A.M."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"Lal S.M."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/author"Lal S.M."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/name"ACS Infect. Dis."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/name"ACS Infect Dis"xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/pages"175-184"xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/pages"175-184"xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/title"Molecular Mechanism of Avibactam-Mediated beta-Lactamase Inhibition."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/title"Molecular Mechanism of Avibactam-Mediated beta-Lactamase Inhibition."xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/volume"1"xsd:string
http://purl.uniprot.org/citations/27622530http://purl.uniprot.org/core/volume"1"xsd:string